Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Light Sciences Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: -

Website: http://www.lsoncology.com/

Clinical Trials

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Saline
Drug: talaporfin sodium
Device: Drug Activator 200 J/cm
Device: Drug Activator 100 J/cm

First Posted Date: 2014-12-29

Last Posted Date: 2018-08-08

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 225

Registration Number: NCT02326454

Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms

Interventions: Drug: talaporfin sodium
Device: Transurethral illumination with light emitting diodes
Procedure: Placement

First Posted Date: 2009-06-11

Last Posted Date: 2012-11-16

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 21

Registration Number: NCT00918034

Locations: 🇦🇺
Royal Brisbane and Women's Hospital Center of Clinical Research, Herston, Australia
🇦🇺
Bayside Urology, Mentone, Australia
🇦🇺
Princess Alexandra Hospital, Wolloongabba, Australia

and more 5 locations

Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Phase 1

Completed

Conditions: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms

Interventions: Drug: Talaporfin sodium
Procedure: Placement of device in prostate urethra
Device: Transurethral illumination with light emitting diodes (Litx™ BPH Device)

First Posted Date: 2008-07-03

Last Posted Date: 2012-11-16

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 12

Registration Number: NCT00709488

Locations: 🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸
UCLA School of Medicine, GU Clinical Trials Office, Los Angeles, California, United States
🇺🇸
The Portland Clinic, Portland, Oregon, United States

and more 3 locations

Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases

Phase 3

Completed

Conditions: Liver Metastases
Neoplasm Metastasis
Colorectal Neoplasms
Neoplasm Recurrence, Local

Interventions: Drug: Talaporfin sodium
Drug: FOLFOX4 regimen
Procedure: Percutaneous placement of device in liver metastases
Device: Interstitial light emitting diodes
Drug: FOLFIRI regimen

First Posted Date: 2007-02-27

Last Posted Date: 2015-08-25

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 483

Registration Number: NCT00440310

Locations: 🇦🇹
Landeskrankenhaus Feldkirch, Feldkirch, Austria
🇦🇹
Krankenhaus Hietzing mit Neurologischen Zentrum Rosenhugel, Wien, Austria
🇧🇦
Clinical Hospital Mostar, Internal Clinic, Department of Gastroenterology, Mostar, Bosnia and Herzegovina

and more 54 locations

Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

Phase 2

Completed

Conditions: Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma

First Posted Date: 2006-12-08

Last Posted Date: 2012-11-16

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 18

Registration Number: NCT00409214

Locations: 🇷🇸
Institute of Neurosurgery, Clinical Centre Serbia, Belgrade, Serbia

A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

Phase 3

Completed

Conditions: Liver Neoplasms
Carcinoma, Hepatocellular

Interventions: Drug: Talaporfin sodium
Procedure: Standard Care
Device: Interstitial Light Emitting Diodes
Procedure: Percutaneous placement of device in the liver

First Posted Date: 2006-07-21

Last Posted Date: 2015-01-30

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 208

Registration Number: NCT00355355

Locations: 🇭🇷
University Hospital Dubrava, Zagreb, Croatia
🇭🇰
Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong
🇭🇰
Prince of Wales Hospital, Dept. of Clincal Oncology, New Territories, Hong Kong

and more 31 locations

Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular
Liver Neoplasms

First Posted Date: 2005-07-22

Last Posted Date: 2007-12-07

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 25

Registration Number: NCT00122876

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
🇸🇬
Singapore General Hospital, Singapore, Singapore

and more 6 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy